Sign in
ARTLW Stock Price, Chart, Stats & News
Artelo Biosciences, Inc.
Save
Artelo Biosciences, Inc. (ARTLW) does not currently pay a dividend.
13,069
Market cap
–
Current P/E
–
Forward P/E
ARTLW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -459.80% |
ROE | 1937.42% |
D/E | -0.54x |
Interest coverage ratio | -20.36x |
ARTLW valuation
P/E | – |
P/S | – |
P/B | -19.53x |
P/CF | -2.52x |
P/FCF | -2.27x |
P/OCF | -2.52x |
PEG | -0.37x |
EV multiple | -1.81x |
About
Artelo Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing and commercializing therapeutic agents that interact with the endocannabinoid system. The company's portfolio of drug candidates features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is currently undergoing Phase 1b/2a clinical trials for the management of anorexia linked to cancer. Another promising candidate is ART12.11, a synthetic cannabidiol cocrystal being explored for its potential in treating inflammatory bowel disease and post-traumatic stress disorder (PTSD).
Similar securities
Based on sector and market capitalization
Report issue